A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's Disease.

ABSTRACT:

Background and aims

Lower-cost biosimilar infliximab may address affordability concerns in the treatment of adults with Crohn's disease (CD), however, evidence regarding the cost-effectiveness of switching from reference to biosimilar is warranted. The aim of this research was to assess the incremental cost of switching from treatment with reference infliximab to biosimilar compared with maintaining reference infliximab in adults with CD per quality-adjusted life year (QALY) gained.

Methods

A probabilistic cohort Markov model with 8-week cycle lengths was constructed to estimate the incremental costs and effects of switching over a 5-year time horizon from a public payer perspective. Base-case clinical inputs were obtained from NOR-SWITCH subgroup analyses and other publishe

SUBMITTER: Hughes A 

PROVIDER: S-EPMC7898373 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature